KarnaTeq, Inc.

BERKELEY, CA · Founded 2019 · CIK 0001788048 · Biotech · Private

OTTR™, a next-generation sequencing (NGS) library preparation method for RNA and DNA

karnateq.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$250K
1 Form D · Sep 2019
84 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$250,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2617Impact Proteomics, LLC—$250K
2618Oxalo Therapeutics, Inc.—$250K
2619Repertoire Immune Medicines——
2620KarnaTeq, Inc.—$250K
2621ROME Therapeutics——
2622MSM PROTEIN TECHNOLOGIES, INC—$250K
2623SNC THERAPEUTICS, INC.—$250K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Kathleen CollinsDirector
  • Michael FinneyDirector
  • Robert KleinDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.